



**AAVBC**

AMERICAN ACADEMY OF VALUE BASED CARE

# **Diabetic Eye Disease**

## **Quick Reference Guide**

2026

## Table of Contents

|                                                                                        |           |
|----------------------------------------------------------------------------------------|-----------|
| <b>1. CLINICAL SNAPSHOT .....</b>                                                      | <b>3</b>  |
| HCC/RAF V28 Mapping .....                                                              | 4         |
| <b>2. RECOGNITION AND DIAGNOSIS .....</b>                                              | <b>6</b>  |
| Medicare Diagnostics and Surveillance (Adult and Geriatric) .....                      | 6         |
| Type 1 vs Type 2 Diabetes: Retinopathy Screening .....                                 | 7         |
| Subtle Early Signs in Older Adults (>65) .....                                         | 8         |
| Geriatric Risk Factors .....                                                           | 9         |
| Diagnostic Thresholds .....                                                            | 10        |
| Common Oversights .....                                                                | 11        |
| Key Differentials in Elderly .....                                                     | 12        |
| Comorbidity Screening .....                                                            | 13        |
| Disease Staging and Severity Matrix .....                                              | 14        |
| <b>3. MEAT DOCUMENTATION AND ESSENTIALS .....</b>                                      | <b>16</b> |
| Clinical Documentation Elements .....                                                  | 17        |
| Reframing Common Documentation Shortcuts .....                                         | 18        |
| <b>4. TREATMENT AND REFERRAL QUICK GUIDE .....</b>                                     | <b>19</b> |
| Therapy Escalation Criteria .....                                                      | 19        |
| AAO PPP 2024 + ADA 2026 + Endocrine Society-Aligned Treatment by Patient Profile ..... | 20        |
| Non-Pharmacologic Treatment and Lifestyle Modification .....                           | 22        |
| Medication Safety and Key Interactions .....                                           | 23        |
| When to Refer .....                                                                    | 24        |
| Follow-Up Timing .....                                                                 | 25        |
| Comorbidity Management .....                                                           | 26        |
| Patient Education and Adherence .....                                                  | 27        |
| Quality Metrics Tie-In .....                                                           | 28        |
| <b>5. CODING REMINDERS AND CASE EXAMPLES .....</b>                                     | <b>30</b> |
| Coding Specificity .....                                                               | 30        |
| Annual Clinical Review and Confirmation .....                                          | 31        |
| Good Documentation Is Comprehensive Coding .....                                       | 32        |
| Brief Case Examples .....                                                              | 33        |
| <b>REFERENCES .....</b>                                                                | <b>34</b> |

## 1 CLINICAL SNAPSHOT

**Definition:** Diabetic retinopathy (DR) is a progressive **neurovascular complication of chronic hyperglycemia** in type 1 or type 2 diabetes. Persistent hyperglycemia promotes glycation, oxidative stress, inflammation, endothelial injury, and breakdown of the blood-retinal barrier. These changes cause **capillary leakage, microaneurysms, retinal hemorrhage, ischemia, and abnormal neovascularization**. DR progresses from mild, moderate, or severe nonproliferative diabetic retinopathy (NPDR) to proliferative diabetic retinopathy (PDR). **Diabetic macular edema (DME)** may occur at any stage when damaged retinal vessels leak fluid into the macula.<sup>1,2</sup> Severe NPDR, PDR, and center-involved DME are vision-threatening and may lead to vitreous hemorrhage, tractional retinal detachment, and irreversible vision loss.<sup>2,3</sup>

### ICD-10 Codes:

Diabetic retinopathy codes require four documented elements: **diabetes type, retinopathy severity, macular-edema status, and laterality**. Use the complete code identified from the ophthalmology diagnosis. Examples include **E11.3411/E11.3412/E11.3413** for severe NPDR with macular edema in the right, left, or bilateral eyes and **E11.3491/E11.3492/E11.3493** for severe NPDR without macular edema. Avoid abbreviated code stems in the final assessment when the complete laterality-specific code is known.<sup>2,4-6</sup>

**Prevalence:** Diabetic retinopathy affects approximately **one-quarter of U.S. adults with diabetes**, and about **5.1% have vision-threatening disease**, including severe NPDR, PDR, or diabetic macular edema. Recent U.S. estimates indicate that approximately **9.6 million people** are living with diabetic retinopathy, including **1.84 million with vision-threatening diabetic retinopathy**.<sup>1,7</sup> Risk rises with **longer diabetes duration, poor glycemic control, hypertension, chronic kidney disease, albuminuria, pregnancy, and missed retinal screening**. Retinopathy generally develops **≥5 years after the onset of type 1 diabetes** but may already be present at the time of **type 2 diabetes diagnosis**. After approximately **20 years of type 1 diabetes, nearly all patients show some degree of retinopathy**, and a substantial proportion develop proliferative disease. Diabetic retinopathy may remain clinically silent until advanced; many patients with mild or even vision-threatening disease are unaware that retinal damage is present. Screening gaps remain common, especially in underserved and older populations, increasing the risk of preventable vision loss, falls, medication errors, loss of independence, depression, transportation barriers, and caregiver dependence.<sup>8-10</sup>

# AAVBC Knowledge Hub Premium Content Access

Continue reading your guide  
with an AAVBC subscription

[Subscribe Now](#)

Already a subscriber? [Sign in](#)

Limited offer

## Basic Membership Free

Includes access to downloadable Quick Reference Guides, mailing list for industry updates/medical information, research toolkits, AAVBC events and so much more!

Cancel at any time